Trial Profile

A phase 1b trial of VYN 202 in moderate-to-severe plaque psoriasis patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Apr 2025 According to a VYNE Therapeutics media release, U.S. Food and Drug Administration (FDA) placed a clinical hold on the Company Phase 1b study evaluating VYN202 for the treatment of moderate-to-severeplaque psoriasis. The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology study with VYN202.
19 Feb 2025 According to a VYNE Therapeutics media release, company announced that the first subject has been dosed in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. Top-line data from the 12-week randomized, placebo-controlled trial are expected by year-end 2025.
19 Feb 2025 Status changed from planning to recruiting, according to VYNE Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com